GSK can now offer Hibsago to some adults with chronic hepatitis B, creating a chance to add sales. Use is limited to adults without cirrhosis already receiving another hepatitis B medicine, and the story gives no sales figures.
This gives GSK another approved treatment to offer a defined group of adults, creating a chance to add sales. The group is limited to adults without cirrhosis who already receive another hepatitis B medicine. The story reports no patient use or sales figures.
The approval is a win for Ionis's partnership, and the story says Hibsago uses technology Ionis pioneered. It gives no payment or sales details, so the size of any benefit is unknown.
Follow GSK (GSK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GSK